Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column.
A fully automated method has been developed for the analysis of a new antifungal agent, voriconazole, in human plasma. Multidimensional chromatography was used with size-exclusion chromatography as the first step to separate plasma protein from the drug and internal standard which were then trapped on a precolumn of pellicular ODS. A reversed-phase column, Spherisorb ODS2, then separated drug and internal standard from one another and from remaining plasma components. With an injection of 0.56 ml plasma the limit of quantitation of the method was 5 ng/ml.
Stopher
D A
DA
Department of Drug Metabolism, Pfizer Central Research, Sandwich, Kent, UK.
Gage
R
R
D000935:Antifungal Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004355:Drug Stability; D006801:Humans; D011743:Pyrimidines / Q000097:blood*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014230:Triazoles / Q000097:blood*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole